OBJECTIVE: To identify subsets of CD4 T lymphocytes that can predict the development of AIDS and to assess whether increased levels of these cellular markers could provide additional independent prognostic information to the CD4 T cell count and plasma HIV-1-RNA levels. DESIGN AND METHODS: In a prospective study, a cohort of 85 HIV-positive intravenous drug users [clinical categories of the CDC classification A (n = 48) and B (n = 37)] were followed for a period of 37+/-13 months. Memory and activated CD4 and CD8 T cells were quantitated by three-colour flow cytometry at baseline and expressed as a percentage of total CD4 and CD8 lymphocytes. Clinical evaluations were performed at 6 month intervals. The relationships between these lymphocyte subsets and progression to AIDS were studied using Kaplan-Meier plots and proportional hazards regression models. RESULTS: After adjustment for the level of CD4 T cells and plasma HIV-1-RNA levels, the elevation in the subset CD4+CD38+DR+ was the marker within the functionally distinct subsets of CD4 T lymphocytes with additional prognostic value in bivariate Cox regression models. In multivariate models, increased percentages of CD4+CD38+DR+ T cells provided the strongest independent prognostic information for progression to AIDS (relative hazard, 1.07; P < 0.0001). CONCLUSION: Our results suggest that high levels of CD4+CD38+HLA-DR+ T cells reflect the increasing degree of CD4 T cell activation during the progression of HIV infection, and could be used together with the CD4 T cell and HIV-RNA levels to evaluate more accurately the progressive cellular immune impairment associated with the risk of progression to AIDS.
OBJECTIVE: To identify subsets of CD4 T lymphocytes that can predict the development of AIDS and to assess whether increased levels of these cellular markers could provide additional independent prognostic information to the CD4 T cell count and plasma HIV-1-RNA levels. DESIGN AND METHODS: In a prospective study, a cohort of 85 HIV-positive intravenous drug users [clinical categories of the CDC classification A (n = 48) and B (n = 37)] were followed for a period of 37+/-13 months. Memory and activated CD4 and CD8 T cells were quantitated by three-colour flow cytometry at baseline and expressed as a percentage of total CD4 and CD8 lymphocytes. Clinical evaluations were performed at 6 month intervals. The relationships between these lymphocyte subsets and progression to AIDS were studied using Kaplan-Meier plots and proportional hazards regression models. RESULTS: After adjustment for the level of CD4 T cells and plasma HIV-1-RNA levels, the elevation in the subset CD4+CD38+DR+ was the marker within the functionally distinct subsets of CD4 T lymphocytes with additional prognostic value in bivariate Cox regression models. In multivariate models, increased percentages of CD4+CD38+DR+ T cells provided the strongest independent prognostic information for progression to AIDS (relative hazard, 1.07; P < 0.0001). CONCLUSION: Our results suggest that high levels of CD4+CD38+HLA-DR+ T cells reflect the increasing degree of CD4 T cell activation during the progression of HIV infection, and could be used together with the CD4 T cell and HIV-RNA levels to evaluate more accurately the progressive cellular immune impairment associated with the risk of progression to AIDS.
Authors: David L Pitrak; Richard M Novak; Randee Estes; Jean Tschampa; Christina D Abaya; Jeffrey Martinson; Kirsten Bradley; Allan R Tenorio; Alan L Landay Journal: AIDS Res Hum Retroviruses Date: 2014-11-11 Impact factor: 2.205
Authors: Christina L Lancioni; C Scott Mahan; Denise F Johnson; Maria Walusimbi; Keith A Chervenak; Sophie Nalukwago; Edwin Charlebois; Diane Havlir; Harriet Mayanja-Kizza; Christopher C Whalen; W Henry Boom Journal: J Infect Dis Date: 2011-04-01 Impact factor: 5.226
Authors: Peter W Hunt; Hiroyu Hatano; Elizabeth Sinclair; Tzong-Hae Lee; Michael P Busch; Jeffrey N Martin; Joseph M McCune; Steven G Deeks Journal: Clin Infect Dis Date: 2011-01-18 Impact factor: 9.079
Authors: Angélique Biancotto; Jean-Charles Grivel; Sarah J Iglehart; Christophe Vanpouille; Andrea Lisco; Scott F Sieg; Robert Debernardo; Kristen Garate; Benigno Rodriguez; Leonid B Margolis; Michael M Lederman Journal: Blood Date: 2007-02-08 Impact factor: 22.113
Authors: Alan Landay; Lorie Benning; James Bremer; Barbara Weiser; Harold Burger; Marek Nowicki; Andrea Kovacs Journal: J Infect Dis Date: 2003-07-01 Impact factor: 5.226
Authors: Gail Skowron; John G Spritzler; Jodi Weidler; Gregory K Robbins; Victoria A Johnson; Ellen S Chan; David M Asmuth; Rajesh T Gandhi; Yolanda Lie; Michael Bates; Richard B Pollard Journal: J Acquir Immune Defic Syndr Date: 2009-03-01 Impact factor: 3.731